Key statistics
As of last trade Bolt Biotherapeutics Inc (6LP:STU) traded at 0.549, 2.81% above its 52-week low of 0.534, set on Sep 16, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.549 |
---|---|
High | 0.549 |
Low | 0.549 |
Bid | 0.543 |
Offer | 0.564 |
Previous close | 0.558 |
Average volume | 0.00 |
---|---|
Shares outstanding | 38.26m |
Free float | 36.94m |
P/E (TTM) | -- |
Market cap | 23.65m USD |
EPS (TTM) | -1.74 USD |
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Announcements
- Bolt Biotherapeutics Announces Changes to its Board of Directors
- Bolt Biotherapeutics to Participate in Upcoming September Conferences
- Bolt Biotherapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
- Bolt Biotherapeutics Reports First Quarter 2024 Results, Announces Strategic Pipeline Prioritization and Changes to Leadership Team
- Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
- Bolt Biotherapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
- Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu®
- Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
- Bolt Biotherapeutics to Present at Stifel 2023 Healthcare Conference
- Bolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress
More ▼